Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma

Exclusion Criteria

• •Contraindication to any drug included in the treatment regimen.
• •History of clinically significant liver disease, including viral or other hepatitis or cirrhosis.
• •Hepatitis B: Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with HBV-DNA above ULN.
• •Active hepatitis C: Positive HCV antibody with detectable HCV-RNA.
• •Human Immunodeficiency Virus (HIV) infection.
• •Congestive heart failure (New York Heart Association Class \> II) or history within 6 months of acute myocardial infarction, unstable angina, stroke, or transient ischemic attack.
• •Hereditary long QT syndrome or QTc \> 480 ms (QTc calculated using Fridericia's formula, QTcF = QT / RR\^0.33).
• •Other malignancies within 5 years, except: completely cured cervical carcinoma in situ, basal cell carcinoma of the skin, breast carcinoma in situ, or another primary cancer that has been cured and not recurred within 5 years.
• •Pregnant or lactating women, or women planning pregnancy during the study period.
• •History of significant neurological or psychiatric disorders, including substance or psychotropic-drug abuse.
• •Clinically significant active infection.
• •Inability to take or swallow oral medication, or conditions affecting drug absorption (e.g., chronic diarrhea, intestinal obstruction).